http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 01 Jun 2026 08:01:20 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Steffen+Heeger+as+chief+medical+officer/26579581.html <p>Actinium Pharmaceuticals Inc. (NYSE American: ATNM) appointed Steffen Heeger, MD, MSc, as chief medical officer, according to a company statement.</p> <p>Heeger previously served as chief medical officer at Full-Life Technologies, where he led global development of radiotherapy programs. He also held the CMO position at NBE-Therapeutics, which was acquired by Boehringer Ingelberg for $1.4 billion.</p> <p>Earlier in his career, Heeger worked at Merck KGaA, where he led clinical development for Erbitux (cetuximab) across multiple cancer types including colorectal, head and neck, gastric, and lung cancers in the United States, Europe, Japan, and China.</p> <p>At MorphoSys AG, he served as vice president and head http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Steffen+Heeger+as+chief+medical+officer/26579581.html Mon, 01 Jun 2026 08:01:20 -0400 0ACX A.31197700 A.35590763 ATNM CNTA O.00284673 O.00831659 O.06705834 O.41084947 O.49013836 SLV http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Steffen+Heeger+as+chief+medical+officer/26579581.html <p>Actinium Pharmaceuticals Inc. (NYSE American: ATNM) appointed Steffen Heeger, MD, MSc, as chief medical officer, according to a company statement.</p> <p>Heeger previously served as chief medical officer at Full-Life Technologies, where he led global development of radiotherapy programs. He also held the CMO position at NBE-Therapeutics, which was acquired by Boehringer Ingelberg for $1.4 billion.</p> <p>Earlier in his career, Heeger worked at Merck KGaA, where he led clinical development for Erbitux (cetuximab) across multiple cancer types including colorectal, head and neck, gastric, and lung cancers in the United States, Europe, Japan, and China.</p> <p>At MorphoSys AG, he served as vice president and head http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Steffen+Heeger+as+chief+medical+officer/26579581.html Mon, 01 Jun 2026 08:01:20 -0400 0ACX A.31197700 A.35590763 ATNM CNTA O.00284673 O.00831659 O.06705834 O.41084947 O.49013836 SLV http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Steffen+Heeger+as+chief+medical+officer/26579581.html <p>Actinium Pharmaceuticals Inc. (NYSE American: ATNM) appointed Steffen Heeger, MD, MSc, as chief medical officer, according to a company statement.</p> <p>Heeger previously served as chief medical officer at Full-Life Technologies, where he led global development of radiotherapy programs. He also held the CMO position at NBE-Therapeutics, which was acquired by Boehringer Ingelberg for $1.4 billion.</p> <p>Earlier in his career, Heeger worked at Merck KGaA, where he led clinical development for Erbitux (cetuximab) across multiple cancer types including colorectal, head and neck, gastric, and lung cancers in the United States, Europe, Japan, and China.</p> <p>At MorphoSys AG, he served as vice president and head http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Steffen+Heeger+as+chief+medical+officer/26579581.html Mon, 01 Jun 2026 08:01:20 -0400 0ACX A.31197700 A.35590763 ATNM CNTA O.00284673 O.00831659 O.06705834 O.41084947 O.49013836 SLV http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Steffen+Heeger+as+chief+medical+officer/26579581.html <p>Actinium Pharmaceuticals Inc. (NYSE American: ATNM) appointed Steffen Heeger, MD, MSc, as chief medical officer, according to a company statement.</p> <p>Heeger previously served as chief medical officer at Full-Life Technologies, where he led global development of radiotherapy programs. He also held the CMO position at NBE-Therapeutics, which was acquired by Boehringer Ingelberg for $1.4 billion.</p> <p>Earlier in his career, Heeger worked at Merck KGaA, where he led clinical development for Erbitux (cetuximab) across multiple cancer types including colorectal, head and neck, gastric, and lung cancers in the United States, Europe, Japan, and China.</p> <p>At MorphoSys AG, he served as vice president and head http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Steffen+Heeger+as+chief+medical+officer/26579581.html Mon, 01 Jun 2026 08:01:20 -0400 0ACX A.31197700 A.35590763 ATNM CNTA O.00284673 O.00831659 O.06705834 O.41084947 O.49013836 SLV http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Steffen+Heeger+as+chief+medical+officer/26579581.html <p>Actinium Pharmaceuticals Inc. (NYSE American: ATNM) appointed Steffen Heeger, MD, MSc, as chief medical officer, according to a company statement.</p> <p>Heeger previously served as chief medical officer at Full-Life Technologies, where he led global development of radiotherapy programs. He also held the CMO position at NBE-Therapeutics, which was acquired by Boehringer Ingelberg for $1.4 billion.</p> <p>Earlier in his career, Heeger worked at Merck KGaA, where he led clinical development for Erbitux (cetuximab) across multiple cancer types including colorectal, head and neck, gastric, and lung cancers in the United States, Europe, Japan, and China.</p> <p>At MorphoSys AG, he served as vice president and head http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Steffen+Heeger+as+chief+medical+officer/26579581.html Mon, 01 Jun 2026 08:01:20 -0400 0ACX A.31197700 A.35590763 ATNM CNTA O.00284673 O.00831659 O.06705834 O.41084947 O.49013836 SLV http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Steffen+Heeger+as+chief+medical+officer/26579581.html <p>Actinium Pharmaceuticals Inc. (NYSE American: ATNM) appointed Steffen Heeger, MD, MSc, as chief medical officer, according to a company statement.</p> <p>Heeger previously served as chief medical officer at Full-Life Technologies, where he led global development of radiotherapy programs. He also held the CMO position at NBE-Therapeutics, which was acquired by Boehringer Ingelberg for $1.4 billion.</p> <p>Earlier in his career, Heeger worked at Merck KGaA, where he led clinical development for Erbitux (cetuximab) across multiple cancer types including colorectal, head and neck, gastric, and lung cancers in the United States, Europe, Japan, and China.</p> <p>At MorphoSys AG, he served as vice president and head http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Steffen+Heeger+as+chief+medical+officer/26579581.html Mon, 01 Jun 2026 08:01:20 -0400 0ACX A.31197700 A.35590763 ATNM CNTA O.00284673 O.00831659 O.06705834 O.41084947 O.49013836 SLV http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Steffen+Heeger+as+chief+medical+officer/26579581.html <p>Actinium Pharmaceuticals Inc. (NYSE American: ATNM) appointed Steffen Heeger, MD, MSc, as chief medical officer, according to a company statement.</p> <p>Heeger previously served as chief medical officer at Full-Life Technologies, where he led global development of radiotherapy programs. He also held the CMO position at NBE-Therapeutics, which was acquired by Boehringer Ingelberg for $1.4 billion.</p> <p>Earlier in his career, Heeger worked at Merck KGaA, where he led clinical development for Erbitux (cetuximab) across multiple cancer types including colorectal, head and neck, gastric, and lung cancers in the United States, Europe, Japan, and China.</p> <p>At MorphoSys AG, he served as vice president and head http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Steffen+Heeger+as+chief+medical+officer/26579581.html Mon, 01 Jun 2026 08:01:20 -0400 0ACX A.31197700 A.35590763 ATNM CNTA O.00284673 O.00831659 O.06705834 O.41084947 O.49013836 SLV http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Steffen+Heeger+as+chief+medical+officer/26579581.html <p>Actinium Pharmaceuticals Inc. (NYSE American: ATNM) appointed Steffen Heeger, MD, MSc, as chief medical officer, according to a company statement.</p> <p>Heeger previously served as chief medical officer at Full-Life Technologies, where he led global development of radiotherapy programs. He also held the CMO position at NBE-Therapeutics, which was acquired by Boehringer Ingelberg for $1.4 billion.</p> <p>Earlier in his career, Heeger worked at Merck KGaA, where he led clinical development for Erbitux (cetuximab) across multiple cancer types including colorectal, head and neck, gastric, and lung cancers in the United States, Europe, Japan, and China.</p> <p>At MorphoSys AG, he served as vice president and head http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Steffen+Heeger+as+chief+medical+officer/26579581.html Mon, 01 Jun 2026 08:01:20 -0400 0ACX A.31197700 A.35590763 ATNM CNTA O.00284673 O.00831659 O.06705834 O.41084947 O.49013836 SLV http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Steffen+Heeger+as+chief+medical+officer/26579581.html <p>Actinium Pharmaceuticals Inc. (NYSE American: ATNM) appointed Steffen Heeger, MD, MSc, as chief medical officer, according to a company statement.</p> <p>Heeger previously served as chief medical officer at Full-Life Technologies, where he led global development of radiotherapy programs. He also held the CMO position at NBE-Therapeutics, which was acquired by Boehringer Ingelberg for $1.4 billion.</p> <p>Earlier in his career, Heeger worked at Merck KGaA, where he led clinical development for Erbitux (cetuximab) across multiple cancer types including colorectal, head and neck, gastric, and lung cancers in the United States, Europe, Japan, and China.</p> <p>At MorphoSys AG, he served as vice president and head http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Steffen+Heeger+as+chief+medical+officer/26579581.html Mon, 01 Jun 2026 08:01:20 -0400 0ACX A.31197700 A.35590763 ATNM CNTA O.00284673 O.00831659 O.06705834 O.41084947 O.49013836 SLV http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Steffen+Heeger+as+chief+medical+officer/26579581.html <p>Actinium Pharmaceuticals Inc. (NYSE American: ATNM) appointed Steffen Heeger, MD, MSc, as chief medical officer, according to a company statement.</p> <p>Heeger previously served as chief medical officer at Full-Life Technologies, where he led global development of radiotherapy programs. He also held the CMO position at NBE-Therapeutics, which was acquired by Boehringer Ingelberg for $1.4 billion.</p> <p>Earlier in his career, Heeger worked at Merck KGaA, where he led clinical development for Erbitux (cetuximab) across multiple cancer types including colorectal, head and neck, gastric, and lung cancers in the United States, Europe, Japan, and China.</p> <p>At MorphoSys AG, he served as vice president and head http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Steffen+Heeger+as+chief+medical+officer/26579581.html Mon, 01 Jun 2026 08:01:20 -0400 0ACX A.31197700 A.35590763 ATNM CNTA O.00284673 O.00831659 O.06705834 O.41084947 O.49013836 SLV http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Steffen+Heeger+as+chief+medical+officer/26579581.html <p>Actinium Pharmaceuticals Inc. (NYSE American: ATNM) appointed Steffen Heeger, MD, MSc, as chief medical officer, according to a company statement.</p> <p>Heeger previously served as chief medical officer at Full-Life Technologies, where he led global development of radiotherapy programs. He also held the CMO position at NBE-Therapeutics, which was acquired by Boehringer Ingelberg for $1.4 billion.</p> <p>Earlier in his career, Heeger worked at Merck KGaA, where he led clinical development for Erbitux (cetuximab) across multiple cancer types including colorectal, head and neck, gastric, and lung cancers in the United States, Europe, Japan, and China.</p> <p>At MorphoSys AG, he served as vice president and head http://www.streetinsider.com/Management+Changes/Actinium+Pharmaceuticals+names+Steffen+Heeger+as+chief+medical+officer/26579581.html Mon, 01 Jun 2026 08:01:20 -0400 0ACX A.31197700 A.35590763 ATNM CNTA O.00284673 O.00831659 O.06705834 O.41084947 O.49013836 SLV http://www.streetinsider.com/Press+Releases/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html <div class="xn-content"> <ul type="disc"><li>Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical through global approvals across hematologic malignancies and solid tumors</li><li>Played a leading role in clinical development and worldwide approvals of Erbitux® at Merck KGaA leading to its blockbuster status</li><li>Led clinical development as CMO of NBE Therapeutics which was acquired by <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span> for <money>$1.4 billion</money>, and most recently CMO of radiotherapy company Full-Life Technologies</li><li>Timely key hire with <person>Dr. Heeger's</person> operational rigor and clinical expertise expected to elevate development of Actimab-A, ATNM-400, and Iomab-ACT http://www.streetinsider.com/Press+Releases/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html Mon, 01 Jun 2026 08:00:00 -0400 0ACX A.31197700 A.35590763 ATNM CNTA O.00284673 O.00831659 O.06705834 O.41084947 O.49013836 SLV http://www.streetinsider.com/Press+Releases/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html <div class="xn-content"> <ul type="disc"><li>Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical through global approvals across hematologic malignancies and solid tumors</li><li>Played a leading role in clinical development and worldwide approvals of Erbitux® at Merck KGaA leading to its blockbuster status</li><li>Led clinical development as CMO of NBE Therapeutics which was acquired by <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span> for <money>$1.4 billion</money>, and most recently CMO of radiotherapy company Full-Life Technologies</li><li>Timely key hire with <person>Dr. Heeger's</person> operational rigor and clinical expertise expected to elevate development of Actimab-A, ATNM-400, and Iomab-ACT http://www.streetinsider.com/Press+Releases/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html Mon, 01 Jun 2026 08:00:00 -0400 0ACX A.31197700 A.35590763 ATNM CNTA O.00284673 O.00831659 O.06705834 O.41084947 O.49013836 SLV http://www.streetinsider.com/Press+Releases/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html <div class="xn-content"> <ul type="disc"><li>Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical through global approvals across hematologic malignancies and solid tumors</li><li>Played a leading role in clinical development and worldwide approvals of Erbitux® at Merck KGaA leading to its blockbuster status</li><li>Led clinical development as CMO of NBE Therapeutics which was acquired by <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span> for <money>$1.4 billion</money>, and most recently CMO of radiotherapy company Full-Life Technologies</li><li>Timely key hire with <person>Dr. Heeger's</person> operational rigor and clinical expertise expected to elevate development of Actimab-A, ATNM-400, and Iomab-ACT http://www.streetinsider.com/Press+Releases/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html Mon, 01 Jun 2026 08:00:00 -0400 0ACX A.31197700 A.35590763 ATNM CNTA O.00284673 O.00831659 O.06705834 O.41084947 O.49013836 SLV http://www.streetinsider.com/Press+Releases/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html <div class="xn-content"> <ul type="disc"><li>Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical through global approvals across hematologic malignancies and solid tumors</li><li>Played a leading role in clinical development and worldwide approvals of Erbitux® at Merck KGaA leading to its blockbuster status</li><li>Led clinical development as CMO of NBE Therapeutics which was acquired by <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span> for <money>$1.4 billion</money>, and most recently CMO of radiotherapy company Full-Life Technologies</li><li>Timely key hire with <person>Dr. Heeger's</person> operational rigor and clinical expertise expected to elevate development of Actimab-A, ATNM-400, and Iomab-ACT http://www.streetinsider.com/Press+Releases/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html Mon, 01 Jun 2026 08:00:00 -0400 0ACX A.31197700 A.35590763 ATNM CNTA O.00284673 O.00831659 O.06705834 O.41084947 O.49013836 SLV http://www.streetinsider.com/Press+Releases/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html <div class="xn-content"> <ul type="disc"><li>Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical through global approvals across hematologic malignancies and solid tumors</li><li>Played a leading role in clinical development and worldwide approvals of Erbitux® at Merck KGaA leading to its blockbuster status</li><li>Led clinical development as CMO of NBE Therapeutics which was acquired by <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span> for <money>$1.4 billion</money>, and most recently CMO of radiotherapy company Full-Life Technologies</li><li>Timely key hire with <person>Dr. Heeger's</person> operational rigor and clinical expertise expected to elevate development of Actimab-A, ATNM-400, and Iomab-ACT http://www.streetinsider.com/Press+Releases/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html Mon, 01 Jun 2026 08:00:00 -0400 0ACX A.31197700 A.35590763 ATNM CNTA O.00284673 O.00831659 O.06705834 O.41084947 O.49013836 SLV http://www.streetinsider.com/Press+Releases/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html <div class="xn-content"> <ul type="disc"><li>Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical through global approvals across hematologic malignancies and solid tumors</li><li>Played a leading role in clinical development and worldwide approvals of Erbitux® at Merck KGaA leading to its blockbuster status</li><li>Led clinical development as CMO of NBE Therapeutics which was acquired by <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span> for <money>$1.4 billion</money>, and most recently CMO of radiotherapy company Full-Life Technologies</li><li>Timely key hire with <person>Dr. Heeger's</person> operational rigor and clinical expertise expected to elevate development of Actimab-A, ATNM-400, and Iomab-ACT http://www.streetinsider.com/Press+Releases/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html Mon, 01 Jun 2026 08:00:00 -0400 0ACX A.31197700 A.35590763 ATNM CNTA O.00284673 O.00831659 O.06705834 O.41084947 O.49013836 SLV http://www.streetinsider.com/Press+Releases/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html <div class="xn-content"> <ul type="disc"><li>Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical through global approvals across hematologic malignancies and solid tumors</li><li>Played a leading role in clinical development and worldwide approvals of Erbitux® at Merck KGaA leading to its blockbuster status</li><li>Led clinical development as CMO of NBE Therapeutics which was acquired by <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span> for <money>$1.4 billion</money>, and most recently CMO of radiotherapy company Full-Life Technologies</li><li>Timely key hire with <person>Dr. Heeger's</person> operational rigor and clinical expertise expected to elevate development of Actimab-A, ATNM-400, and Iomab-ACT http://www.streetinsider.com/Press+Releases/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html Mon, 01 Jun 2026 08:00:00 -0400 0ACX A.31197700 A.35590763 ATNM CNTA O.00284673 O.00831659 O.06705834 O.41084947 O.49013836 SLV http://www.streetinsider.com/Press+Releases/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html <div class="xn-content"> <ul type="disc"><li>Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical through global approvals across hematologic malignancies and solid tumors</li><li>Played a leading role in clinical development and worldwide approvals of Erbitux® at Merck KGaA leading to its blockbuster status</li><li>Led clinical development as CMO of NBE Therapeutics which was acquired by <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span> for <money>$1.4 billion</money>, and most recently CMO of radiotherapy company Full-Life Technologies</li><li>Timely key hire with <person>Dr. Heeger's</person> operational rigor and clinical expertise expected to elevate development of Actimab-A, ATNM-400, and Iomab-ACT http://www.streetinsider.com/Press+Releases/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html Mon, 01 Jun 2026 08:00:00 -0400 0ACX A.31197700 A.35590763 ATNM CNTA O.00284673 O.00831659 O.06705834 O.41084947 O.49013836 SLV http://www.streetinsider.com/Press+Releases/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html <div class="xn-content"> <ul type="disc"><li>Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical through global approvals across hematologic malignancies and solid tumors</li><li>Played a leading role in clinical development and worldwide approvals of Erbitux® at Merck KGaA leading to its blockbuster status</li><li>Led clinical development as CMO of NBE Therapeutics which was acquired by <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span> for <money>$1.4 billion</money>, and most recently CMO of radiotherapy company Full-Life Technologies</li><li>Timely key hire with <person>Dr. Heeger's</person> operational rigor and clinical expertise expected to elevate development of Actimab-A, ATNM-400, and Iomab-ACT http://www.streetinsider.com/Press+Releases/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html Mon, 01 Jun 2026 08:00:00 -0400 0ACX A.31197700 A.35590763 ATNM CNTA O.00284673 O.00831659 O.06705834 O.41084947 O.49013836 SLV http://www.streetinsider.com/Press+Releases/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html <div class="xn-content"> <ul type="disc"><li>Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical through global approvals across hematologic malignancies and solid tumors</li><li>Played a leading role in clinical development and worldwide approvals of Erbitux® at Merck KGaA leading to its blockbuster status</li><li>Led clinical development as CMO of NBE Therapeutics which was acquired by <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span> for <money>$1.4 billion</money>, and most recently CMO of radiotherapy company Full-Life Technologies</li><li>Timely key hire with <person>Dr. Heeger's</person> operational rigor and clinical expertise expected to elevate development of Actimab-A, ATNM-400, and Iomab-ACT http://www.streetinsider.com/Press+Releases/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html Mon, 01 Jun 2026 08:00:00 -0400 0ACX A.31197700 A.35590763 ATNM CNTA O.00284673 O.00831659 O.06705834 O.41084947 O.49013836 SLV http://www.streetinsider.com/Press+Releases/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html <div class="xn-content"> <ul type="disc"><li>Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical through global approvals across hematologic malignancies and solid tumors</li><li>Played a leading role in clinical development and worldwide approvals of Erbitux® at Merck KGaA leading to its blockbuster status</li><li>Led clinical development as CMO of NBE Therapeutics which was acquired by <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span> for <money>$1.4 billion</money>, and most recently CMO of radiotherapy company Full-Life Technologies</li><li>Timely key hire with <person>Dr. Heeger's</person> operational rigor and clinical expertise expected to elevate development of Actimab-A, ATNM-400, and Iomab-ACT http://www.streetinsider.com/Press+Releases/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html Mon, 01 Jun 2026 08:00:00 -0400 0ACX A.31197700 A.35590763 ATNM CNTA O.00284673 O.00831659 O.06705834 O.41084947 O.49013836 SLV http://www.streetinsider.com/PRNewswire/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html <div class="xn-content"> <ul type="disc"><li>Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical through global approvals across hematologic malignancies and solid tumors</li><li>Played a leading role in clinical development and worldwide approvals of Erbitux® at Merck KGaA leading to its blockbuster status</li><li>Led clinical development as CMO of NBE Therapeutics which was acquired by <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span> for <money>$1.4 billion</money>, and most recently CMO of radiotherapy company Full-Life Technologies</li><li>Timely key hire with <person>Dr. Heeger's</person> operational rigor and clinical expertise expected to elevate development of Actimab-A, ATNM-400, and Iomab-ACT http://www.streetinsider.com/PRNewswire/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html Mon, 01 Jun 2026 08:00:00 -0400 0ACX A.31197700 A.35590763 ATNM CNTA O.00284673 O.00831659 O.06705834 O.41084947 O.49013836 SLV http://www.streetinsider.com/PRNewswire/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html <div class="xn-content"> <ul type="disc"><li>Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical through global approvals across hematologic malignancies and solid tumors</li><li>Played a leading role in clinical development and worldwide approvals of Erbitux® at Merck KGaA leading to its blockbuster status</li><li>Led clinical development as CMO of NBE Therapeutics which was acquired by <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span> for <money>$1.4 billion</money>, and most recently CMO of radiotherapy company Full-Life Technologies</li><li>Timely key hire with <person>Dr. Heeger's</person> operational rigor and clinical expertise expected to elevate development of Actimab-A, ATNM-400, and Iomab-ACT http://www.streetinsider.com/PRNewswire/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html Mon, 01 Jun 2026 08:00:00 -0400 0ACX A.31197700 A.35590763 ATNM CNTA O.00284673 O.00831659 O.06705834 O.41084947 O.49013836 SLV http://www.streetinsider.com/PRNewswire/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html <div class="xn-content"> <ul type="disc"><li>Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical through global approvals across hematologic malignancies and solid tumors</li><li>Played a leading role in clinical development and worldwide approvals of Erbitux® at Merck KGaA leading to its blockbuster status</li><li>Led clinical development as CMO of NBE Therapeutics which was acquired by <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span> for <money>$1.4 billion</money>, and most recently CMO of radiotherapy company Full-Life Technologies</li><li>Timely key hire with <person>Dr. Heeger's</person> operational rigor and clinical expertise expected to elevate development of Actimab-A, ATNM-400, and Iomab-ACT http://www.streetinsider.com/PRNewswire/Actinium+Appoints+Accomplished+Oncology+Expert+Steffen+Heeger+MD%2C+MSc+as+Chief+Medical+Officer+to+Drive+Rejuvenated+Pipeline+Development/26579471.html Mon, 01 Jun 2026 08:00:00 -0400 0ACX A.31197700 A.35590763 ATNM CNTA O.00284673 O.00831659 O.06705834 O.41084947 O.49013836 SLV